363 related articles for article (PubMed ID: 26369760)
21. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
Ancans J
Front Immunol; 2012; 3():253. PubMed ID: 22912639
[TBL] [Abstract][Full Text] [Related]
22. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
23. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
24. European regulatory tools for advanced therapy medicinal products.
Flory E; Reinhardt J
Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
[TBL] [Abstract][Full Text] [Related]
25. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Dwenger A; Strassburger J; Schwerdtfeger W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
[TBL] [Abstract][Full Text] [Related]
26. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
27. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
[TBL] [Abstract][Full Text] [Related]
28. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
29. [Compassionate use of non-approved medicinal products. Legal basis and guidelines].
Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):439-43. PubMed ID: 19343282
[TBL] [Abstract][Full Text] [Related]
30. Regulatory watch: European regulatory experience with advanced therapy medicinal products.
Barkholt L; Voltz-Girolt C; Raine J; Salmonson T; Schüssler-Lenz M
Nat Rev Drug Discov; 2019 Jan; 18(1):8-9. PubMed ID: 30498203
[No Abstract] [Full Text] [Related]
31. [Advanced therapy medicinal products : Scientific, medical, economic, and ethical aspects].
Seitz R; Schneider CK; Hengel H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):789-90. PubMed ID: 21698529
[No Abstract] [Full Text] [Related]
32. [Regulatory framework of innovative therapies : From bench to bedside].
Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
[TBL] [Abstract][Full Text] [Related]
33. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.
Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P
Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933
[TBL] [Abstract][Full Text] [Related]
34. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
[TBL] [Abstract][Full Text] [Related]
35. CAT--the new committee for advanced therapies at the European Medicines Agency.
Celis P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
[TBL] [Abstract][Full Text] [Related]
36. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
Berger A; Schüle S; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
[TBL] [Abstract][Full Text] [Related]
37. [The therapy allergens ordinance ("Therapieallergene-Verordnung"). Background and effects].
Englert L; May S; Kaul S; Vieths S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):351-7. PubMed ID: 22373848
[TBL] [Abstract][Full Text] [Related]
38. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
[TBL] [Abstract][Full Text] [Related]
39. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
40. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
